Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01235936 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

A Phase 2 study of Anemia and Kidney Disease, sponsored by Akebia Therapeutics.

Completed
Registry status
Phase 2
Development phase
10
Enrollment target
2
Study locations

NCT01235936 is a Phase 2 study of Anemia and Kidney Disease that has completed, run by Akebia Therapeutics. The registered enrollment target is 10 participants, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01235936, a Phase 2 study of Anemia and Kidney Disease, has completed, sponsored by Akebia Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
10 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to evaluate the safety, pharmacodynamics and pharmacokinetics of repeat doses of orally administered AKB-6548 in pre-dialysis participants with anemia.

Conditions Studied

Anemia Kidney Disease

Interventions

  • DRUG AKB-6548

Study Locations (2)

Georgia

  • - Augusta

Texas

  • - San Antonio

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2010-10-21
Est. Completion 2011-05
Phase Phase 2

Sponsor

Akebia Therapeutics

24 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01235936

The ClinicalTrials.gov registry entry for NCT01235936 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (98% lower). The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Anemia appearing as the primary indexed condition, and to 1 intervention - of which AKB-6548 is the first listed.

NCT01235936 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Texas.

Frequently Asked Questions

What is clinical trial NCT01235936 about?

NCT01235936 is a clinical study titled "Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia". The purpose of this study is to evaluate the safety, pharmacodynamics and pharmacokinetics of repeat doses of orally administered AKB-6548 in pre-dialysis participants with anemia.

What is the current status of trial NCT01235936?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-10-21. Estimated completion is 2011-05.

What conditions does trial NCT01235936 study?

This clinical trial studies the following conditions: Anemia, Kidney Disease.

What interventions are being tested in trial NCT01235936?

The interventions under investigation include: AKB-6548 (DRUG).

Who is sponsoring clinical trial NCT01235936?

This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01235936 being conducted?

This trial has 2 study locations across Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Anemia

All registered trials for this condition

Kidney Disease

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.